Neuroendocrine regulation of cancer progression: I. Biological mechanisms and clinical relevance

Psychoneuroimmunology, Two-Volume Set

Volumn 1, Issue , 2007, Pages 233-249

  Sood, Anil K ^a   Lutgendorf, Susan K ^b   Steven, Cole W ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882560078     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088576-3/50015-0     Document Type: Chapter

References (244)

1. Spiegel D., Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol. Psychiatry 2003, 54:269-282.
2. Strange K.S., Kerr L.R., Andrews H.N., et al. Psychosocial stressors and mammary tumor growth: an animal model. Neurotoxicol. Teratol. 2000, 22:89-102.
3. Antoni M., Lutgendorf S., Cole S., et al. The influence of biobehavioral factors on tumor biology: pathway and mechanisms. Nature Reviews Cancer 2006, 6:240-248.
4. Justice A. Review of the effects of stress on cancer in laboratory animals: importance of time of stress application and type of tumor. Psychol. Bul. 1985, 98:108-138.
5. Riley V. Psychoneuroendocrine influences on immunocompetence and neoplasia. Science, 1981, 212:1100-1109.
6. Chen C.C., David A.S., Nunnerley H., et al. Adverse life events and breast cancer: case-control study. BMJ 1995, 311:1527-1530.
7. Protheroe D., Turvey K., Horgan K., et al. Stressful life events and difficulties and onset of breast cancer: case-control study. BMJ 1999, 319:1027-1030.
8. Dunn A.J. Psychoneuroimmunology: introduction and general perspectives. Stress, the immune system and psychiatry 1996, 1-16. John Wiley & Sons, Ltd, Chichester. B. E. Leonard, K. Miller (Eds.).
9. Duijts S.F., Zeegers M.P., Borne B.V. The association between stressful life events and breast cancer risk: a metaanalysis. Int. J. Cancer 2003, 107:1023-1029.
10. Petticrew M., Fraser J., Regan M. Adverse lifeevents and risk of breast cancer: a meta-analysis. British Journal of Health Psychology 1999, 4:1-17.
11. McKenna M.C., Zevon M.A., Corn B., et al. Psychosocial factors and the development of breast cancer: a metaanalysis. Health Psychology 1999, 18:520-531.
12. Geyer S. Life events prior to manifestation of breast cancer: a limited prospective study covering eight years before diagnosis. J. Psychosom. Res. 1991, 355-363.
13. Lllberg K., Vaerkasalo P.K., Kaprio J., et al. Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am. J. Epidemiol. 2003, 157:415-423.
14. Levav I., Kohn R., Iscovich J., et al. Cancer incidence and survival following bereavement. Am. J. Public Health 2000, 90:1601-1607.
15. Martikainen P., Valkonen T. Mortality after death of spouse in relation to duration of bereavement in Finland. J. Epidemiol. Community Health 1996, 50:264-268.
16. Giraldi T., Rodani M.G., Cartei G., et al. Psychosocial factors and breast cancer: a 6-year Italian follow-up study. Psychotherapy & Psychosomatics 1997, 66:229-236.
17. Penninx B.W., Guralnik J.M., Pahor M., et al. Chronically depressed mood and cancer risk in older persons. J. Natl. Cancer Inst. 1998, 90:1888-1893.
18. Price M.A., Tennant A.C., Smith R.C., et al. The role of psychosocial factors in the development of breast carcinoma: PART I. The cancer prone personality. Cancer 2001, 91:679-685.
19. Lutgendorf S.K., Costanzo E.S. Psychoneuroimmunology and health psychology: an integrative model. Brain Behav. Immun. 2003, 17:225-232.
20. Shekelle R.B., Raynor W.J., Ostfeld A.M., et al. Psychological depression and 17-year risk of death from cancer. Psychosom. Med. 1981, 43:117-125.
21. Everson S.A., Goldberg D.E., Kaplan G.A., et al. Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom. Med. 1996, 58:113-121.
22. Stommel M., Given B.A., Given C.W. Depression and functional status as predictors of death among cancer patients. Cancer 2002, 94:2719-2727.
23. Watson M., Haviland J.S., Greer S., et al. influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet 1999, 354:1331-1336.
24. Buccheri G. Depressive reactions to lung cancer are common and often followed by a poor outcome. European Respiratory Journal 1998, 11:173-178.
25. Rodrigue J., Pearman T., Moreb J. Morbidity and mortality following bone marrow transplantation: predictive utility of pre-BMT affective functioning, compliance, and social support stability. International Journal of Behavioral Medicine 1999, 6:241-254.
26. Tross S., Herndon J., 2nd Korzun A., et al. Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. J. Natl. Cancer Inst. 1996, 88:661-667.
27. Andrykowski M.A., Brady M.J., Henslee-Downey P.J. Psychosocial factors predictive of survival after allogeneic bone marrow transplantation for leukemia. Psychosom. Med. 1994, 56:432-439.
28. Faller H., Bulzebruck H., Drings P., et al. Coping, distress, and survival among patients with lung cancer. Arch. Gen. Psychiatry 1999, 56:756-762.
29. Barraclough J., Pinder P., Cruddas M., et al. Life events and breast cancer prognosis. BMJ 1992, 304:1078-1081.
30. Maunsell E., Brisson J., Mondor M., et al. Stressful life events and survival after breast cancer. Psychosom. Med. 2001, 63:306-315.
31. Cohen S., Willis T.A. Stress, social support, and the buffering hypothesis. Psychological Bulletin 1985, 98:310-357.
32. Funch D.P., Marshall J. The role of stress, social support and age in survival from breast cancer. Journal of Psychosomatic Research 1983, 27:77-83.
33. Marshall J. R. and Funch D. P., Social environment and breast cancer. A cohort analysis of patient survival. Cancer, 52:1546-1550.
34. Maunsell E., Brisson J. and Deschenes L., Social support and survival among women with breast cancer. Cancer, 76:631-637.
35. eynolds P., Boyd P.T., Blacklow R.S., et al. The relationship between social ties and survival among black and white breast cancer patients. National Cancer Institute Black/ White Cancer Survival Study G. Cancer Epidemiol. Biomarkers Prev. 1994, 3:253-259.
36. Reynolds P., Hurley S., Torres M., et al. Use of coping strategies and breast cancer survival: results from the Black/ White Cancer Survival Study. Am. J. Epidemiol. 2000, 152:940-949.
37. Butow P.N., Hiller J.E., Price M.A., et al. Epidemiological evidence for a relationship between life events, coping style, and personality factors in the development of breast cancer. J. Psychosom. Res. 2000, 49:169-181.
38. Sapolsky R. Why zebras don't get ulcers: a guide to stress, stress-related diseases, and coping 1994, Freeman, New York.
39. Weiner H. Perturbing the organism: the biology of stressful experience 1992, University of Chicago Press, Chicago.
40. Chrousos G.P., Gold P.W. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA, 1992, 267:1244-1252.
41. Charmandari E., Tsigos C., Chrousos G. Endocrinology of the stress response. Annu. Rev. Physiol. 2005, 67:259-284.
42. Lara H.E., Porcile A., Espinoza J., et al. Release of norepinephrine from human ovary: coupling to steroidogenic response. Endocrine Journal 2001, 15:187-192.
43. Greenwald G., Roy S. Follicular development and its control. The physiology of reproduction 1994, 629-724. Raven Press, New York. E. Knobil, J. Neill (Eds.).
44. Nankova B., Kvetnansky R., Hiremagalur B., et al. Immobilization stress elevates gene expression for catecholamine biosynthetic enzymes and some neuropeptides in rat sympathetic ganglia: effects of adrenocort and glucocorticoids. Endocrinology 1996, 137:5597-5604.
45. Paredes A., Galvez A., Leyton V., et al. Stress promotes development of ovarian cysts in rats: the possible role of sympathetic nerve activation. Endocrine 1998, 8:309-315.
46. Lara H.E., Dorfman M., Venegas M., et al. Changes in sympathetic nerve activity of the mammalian ovary during a normal estrous cycle and in polycystic ovary syndrome: studies on norepinephrine release. Microsc. Res. Tech. 2002, 59:495-502.
47. Maestroni G.J. Neurohormones and catecholamines as functional components of the bone marrow microenvironment. Ann. N. Y. Acad. Sci. 2000, 917:29-37.
48. Schmidt C., Kraft K. Beta-endorphin and catecholamine concentrations during chronic and acute stress in intensive care patients. Eur. J. Med. Res. 1996, 1:528-532.
49. Rupp H., Dhalla K. S. and Dhalla N. S., Mechanisms of cardiac cell damage due to catecholamines: significance of drugs regulating central sympathetic out Cardiovasc. Pharmacol. 24(Suppl 1):S16-24.
50. Rupp H., Jacob R. Excess catecholamines and the metabolic syndrome: should central imidazoline receptors be a therapeutic target?. Med. Hypotheses 1995, 44:217-225.
51. Badino G.R., Novelli A., Girardi C., et al. Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacological Research 1996, 33:255-260.
52. Lutgendorf S.K., Cole S., Costanzo E., et al. Stressrelated mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clinical Cancer Research 2003, 9:4514-4521.
53. McDonald P.H., Lefkowitz R.J. Beta-arrestins: new roles in regulating heptahelical receptors' functions. Cell Signal 2001, 13:683-689.
54. Dixon R.A., Kobilka B.K., Strader D.J., et al. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 1986, 321:75-79.
55. Emorine L.J., Marullo S., Briend-Sutren M.M., et al. Molecular characterization of the human beta 3-adrenergic receptor. Science 1989, 245:1118-1121.
56. Frielle T., Collins S., Daniel K.W., et al. Cloning of the cDNA for the human beta 1-adrenergic receptor. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:7920-7924.
57. Ben-Eliyahu S., Yirmiya R., Liebeskind J.C., et al. Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. Brain, Behavior, & Immunity 1991, 5:193-205.
58. Sapolsky R. M., Romero L. M. and Munck A. U., How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions, Endocrine Reviews, 21:55-89.
59. Seeman T., McEwan B. Impact of Social environment characteristics on neuroendocrine regulation. Psychosom. Med. 1996, 58:459-471.
60. Antoni M.H., Cruess D.G., Cruess S., et al. Cognitive-behavioral stress management intervention effects on anxiety, 24-hr urinary norepinephrine output, and T-cytotoxic/ suppressor cells over time among symptomatic HIV-infected gay men. J. Consult. Clin. Psychol. 2000, 68:31-45.
61. Antoni M.H., Cruess S., Cruess D.G., et al. Cognitive-behavioral stress management reduces distress and 24-hour urinary free cortisol output among symptomatic HIVinfected gay men. Ann. Behav. Med. 2000, 22:29-37.
62. Kawamura A., Tamaki N., Kokunai T. Effect of dexamethasone on cell proliferation of neuroepithelial tumor cell lines. Neurologia. Medico-Chirurgica 1998, 38:633-638.
63. Kawamura A., Tamaki N., Kokunai T. Effect of dexamethasone on cell proliferation of neuroepithelial tumor cell lines. Neurologia. Medico-Chirurgica 1998, 38:638-640. discussion,.
64. Nakane T., Szentendrei T., Stern L., et al. Effects of IL-1 and cortisol on beta-adrenergic receptors, cell proliferation, and differentiation in cultured human A549 lung tumor cells. J. Immunol. 1990, 145:260-266.
65. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
66. Vogelstein B., Kinzler K.W. The genetic basis of human cancer 2002, McGraw-Hill Companies,Inc., New York. 2nd ed.
67. Hahn W.C., Counter C.M., Lundberg A.S., et al. Creation of human tumour cells with defined genetic elements. Nature 1999, 400:464-468.
68. Kiecolt-Glaser J.K., Stephens R.E., Lipetz P.D., et al. Distress and DNA repair in human lymphocytes. J. Behav. Med. 1985, 8:311-320.
69. Glaser R., Thorn B.E., Tarr K.L., et al. Effects of stress on methyltransferase synthesis: an important DNA repair enzyme. Health Psychol. 1985, 4:403-412.
70. Fischman H.K., Kelly D.D. Sister chromatid exchanges induced by behavioral stress. Ann. N. Y. Acad. Sci. 1987, 496:426-435.
71. Forlenza M.J., Latimer A.J., Baumi A. The effects of stress on DNA repair capacity. Psychology & Health 2000, 15:881-891.
72. Cavigelli S.A., McClintock M.K. Fear of novelty in infant rats predicts adult corticosterone dynamics and an early death. Proc. Natl. Acad. Sci. USA, 2003, 100:16131-16136.
73. Parker J., Klein S.L., McClintock M.K., et al. Chronic stress accelerates ultraviolet-induced cutaneous carcinogenesis. J. Am. Acad. Dermatol. 2004, 51:919-922.
74. McClintock M.K., Conzen S.D., Gehlert S., et al. Mammary cancer and social interactions: identifying multiple environments that regulate gene expression throughout the life span. J. Gerontol. B Psychol. Sci. Soc. Sci. 2005, 60(Spec No 1):32-41.
75. Jensen M.M. The influence of stress on murine leukemia virus infection. Proc. Soc. Exp. Biol. Med. 1968, 127:610-614.
76. Riley V. Mouse mammary tumors: alteration of incidence as apparent function of stress. Science 1975, 189:465-467.
77. Amkraut A., Solomon G.F. Stress and murine sarcoma virus (Moloney) -induced tumors. Cancer Res. 1972, 32:1428-1433.
78. Everett R. Factors affecting spontaneous tumor incidence rates in mice: a literature review. Crit. Rev. Toxicol. 1984, 13:235-251.
79. Reznikoff M., Martin D.E. The influence of stress on mammary cancer in mice. J. Psychosom. Res. 1957, 2:56-60.
80. Andervont H. influence of environment on mammary cancer in mice. Journal of the National Cancer Institute 1944, 4:579-581.
81. Muhlbock O. influence of environment on the incidence of mammary tumors in mice. Acta Unio. Int. Contra. Cancrum 1951, 7:351-353.
82. Albert Z. Effect of number of animals per cage on the development of spontaneous neoplasms. Husbandry of laboratory animals 1967, AcademicPress, London. M. L. Conalty (Ed.).
83. Riley V., Spackman S. Modifying effects of a benign virus on the malignant process and the role of physiological stress on tumor incidence. Fogarty International Center Proceedings 1976, 28:319-356.
84. Rowse G.L., Weinberg J., Bellward G.D., et al. Endocrine mediation of psychosocial stressor effects on mouse mammary tumor growth. Cancer Letter 1992, 65:85-93.
85. Sapolsky R. M. and Donnelly T. M., Vulnerability to stressinduced tumor growth increases with age in rats: role of glucocorticoids. Endocrinology. 117:662.
86. Rapp F., Reed C.L. The viral etiology of cancer: a realistic approach. Cancer 1977, 40:419-429.
87. Romero L., Raley-Susman K., Redish D., et al. A possible mechanism by which stress accelerates growth of virallyderived tumors. Proceeding of the National Academy of Sciences 1992, 89:11084.
88. McGrath C.M., Jones R.F. Hormonal induction of mammary tumor viruses and its implications for carcinogenesis. Cancer Res. 1978, 38:4112-4125.
89. McGrath C.M., Prass W.A., Maloney T.M., et al. Induction of endogenous mammary tumor virus expression during hormonal induction of mammary adenoacanthomas and carcinomas of BALB/c female mice. J. Natl. Cancer Inst. 1981, 67:841-852.
90. Kalinichenko V.V., Mokyr M.B., Graf L.H., et al. Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene e. J. Immunol. 1999, 163:2492-2499.
91. Cook-Mills J.M., Cohen R.L., Perlman R.L., et al. Inhibition of lymphocyte activation by catecholamines: evidence for a non-classical mechanism of catecholamine action. Immunology 1995, 85:544-549.
92. Cook-Mills J.M., Mokyr M.B., Cohen R.L., et al. Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma. Cancer Immunol. Immunother. 1995, 40:79-87.
93. Melamed R., Rosenne E., Shakhar K., et al. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antago a prostaglandin synthesis inhibitor. Brain Behav. Immun. 2005, 19:114-126.
94. Buchschacher G.L.J., Wong-Staal F. RNA viruses. Cancer: principles and practice of oncology 2005, 165-172. Lippincott Williams & Wilkins, Philadelphia. V. T. J. DeVita, S. Hellman, S. A. Rosenberg (Eds.).
95. Howley P.M., Ganem D., Kieff E. DNA viruses. Cancer: principles and practice of oncology 2005, 173-184. Lippincott Williams & Wilkins, Philadelphia. V. T. J. DeVita, S. Hellman, S. A. Rosenberg (Eds.).
96. zur Hausen H. Viruses in human cancers. Science 1991, 254:1167-1173.
97. Payne D.A., Mehta S.K., Tyring S.K., et al. Incidence of Epstein-Barr virus in astronaut saliva during spaceflight. Aviat. Space Environ. Med. 1999, 70:1211-1213.
98. Tingate T.R., Lugg D.J., Muller H.K., et al. Antarctic isolation: immune and viral studies. Immunol. Cell Biol. 1997, 75:275-283.
99. Glaser R., Kiecolt-Glaser J.K., Speicher C.E., et al. Stress, loneliness, and changes in herpesvirus latency. J. Behav. Med. 1985, 8:249-260.
100. Glaser R., Pearson G.R., Jones J.F., et al. Stress-related activation of Epstein-Barr virus. Brain Behav. Immun. 1991, 5:219-232.
101. Stowe R.P., Pierson D.L., Barrett A.D. Elevated stress hormone levels relate to Epstein-Barr virus reactivation in astronauts. Psychosom Med. 2001, 63:891-895.
102. Cacioppo J.T., Kiecolt-Glaser J.K., Malarkey W.B., et al. Autonomic and glucocorticoid associations with the steady-state expression of latent Epstein-Barr virus. Horm. Behav. 2002, 42:32-41.
103. Glaser R., Kutz L.A., MacCallum R.C., et al. Hormonal modulation of Epstein-Barr virus replication. Neuroendocrinology 1995, 62:356-361.
104. Selvey L.A., Dunn L.A., Tindle R.W., et al. Human papillomavirus (HPV) type 18 E7 protein is a short-lived steroid-inducible phosphoprotein in HPV-transformed cell lines. J. Gen. Virol. 1994, 75:1647-1653. (Pt 7).
105. Bromberg-White J.L., Meyers C. Comparison of the basal and glucocorticoid-inducible activities of the upstream regulatory regions of HPV18 and HPV31 in multiple epithelial cell lines. Virology 2003, 306:197-202.
106. Piccini A., Storey A., Romanos M., et al. Regulation of human papillomavirus type 16 DNA replication by E2, glucocorticoid hormone and epidermal growth factor. J. Gen. Virol. 1997, 78:1963-1970. (Pt 8).
107. Khare S., Pater M.M., Tang S.C., et al. Effect of glucocorticoid hormones on viral gene expression, growth, and dysplastic differentiation in HPV16-immortalized ectocervical cells. Exp. Cell Res. 1997, 232:353-360.
108. Mittal R., Tsutsumi K., Pater A., et al. Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones. Obstet. Gynecol. 1993, 81:5-12.
109. Mittal R., Pater A., Pater M.M. Multiple human papillomavirus type 16 glucocorticoid response elements functional for transformation, transient expression, and DNAprotein interactions. J. Virol. 1993, 67:5656-5659.
110. Cid A., Auewarakul P., Garcia-Carranca A., et al. Celltype-specific activity of the human papillomavirus type 18 upstream regulatory region in transgenic mice and its modulation by tetradecanoyl phorbol acet glucocorticoids. J. Virol. 1993, 67:6742-6752.
111. Gloss B., Bernard H.U., Seedorf K., et al. The upstream regulatory region of the human papilloma virus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and by glucocorticoid hormones. EMBO J. 1987, 6:3735-3743.
112. Durst M., Gallahan D., Jay G., et al. Glucocorticoidenhanced neoplastic transformation of human keratinocytes by human papillomavirus type 16 and an activated ras oncogene. Virology 1989, 173:767-771.
113. Pater M.M., Hughes G.A., Hyslop D.E., et al. Glucocorticoid-dependent oncogenic transformation by type 16 but not type 11 human papilloma virus DNA. Nature 1988, 335:832-835.
114. Bartholomew J.S., Glenville S., Sarkar S., et al. Integration of high-risk human papillomavirus DNA is linked to the down-regulation of class I human leukocyte antigens by steroid hormones in cervical tumor c. Cancer Res. 1997, 57:937-942.
115. Pater M.M., Pater A. RU486 inhibits glucocorticoid hormone-dependent oncogenesis by human papillomavirus type 16 DNA. Virology 1991, 183:799-802.
116. Kamradt M.C., Mohideen N., Krueger E., et al. Inhibition of radiation-induced apoptosis by dexamethasone in cervical carcinoma cell lines depends upon increased HPV E6/E7. Br. J. Cancer 2000, 82:1709-1716.
117. Kamradt M.C., Mohideen N., Vaughan A.T. RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells. Gynecol. Oncol. 2000, 77:177-182.
118. Coker A.L., Bond S., Madeleine A.M., et al. Psychosocial stress and cervical neoplasia risk. Psychosom. Med. 2003, 65:644-651.
119. Pereira D.B., Antoni M.H., Danielson A., et al. Life stress and cervical squamous intraepithelial lesions in women with human papillomavirus and human immunodeficiency virus. Psychosom. Med. 2003, 65:427-434.
120. Tur-Kaspa R., Burk R.D., Lieberman H.H., et al. Hepatitis B virus gene expression in relation to virus replication and HBV-DNA integration. New concepts for antiviral therapy. J. Hepatol. 1986, 3(Suppl 2):S25-S33.
121. Tur-Kaspa R., Shaul Y., Moore D.D., et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988, 167:630-633.
122. Gripon P., Diot C., Corlu A., et al. Regulation by dimethylsulfoxide, insulin, and corticosteroids of hepatitis B virus replication in a transfected human hepatoma cell line. J. Med. Virol. 1989, 28:193-199.
123. Tur-Kaspa R., Laub O. Corticosteroids stimulate hepatitis B virus DNA, mRNA and protein production in a stable expression system. J. Hepatol. 1990, 11:34-36.
124. Chou C.K., Wang L.H., Lin H.M., et al. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 1992, 16:13-18.
125. Magy N., Cribier B., Schmitt C., et al. Effects of corticosteroids on HCV infection. Int J. Immunopharmacol. 1999, 21:253-261.
126. Chayama K., Tsubota A., Kobayashi M., et al. A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C. Hepatology 1996, 23:953-957.
127. Tisone G., Angelico M., Palmieri G., et al. A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation 1999, 67:1308-1313.
128. McHutchison J.G., Ponnudurai R., Bylund D.L., et al. Prednisone withdrawal followed by interferon alpha for treatment of chronic hepatitis C infection: results of a randomized controlled trial. J. Clin. Gastroenterol. 2001, 32:133-137.
129. Yokosuka O. Role of steroid priming in the treatment of chronic hepatitis B. J. Gastroenterol. Hepatol. 2000, 15:E41-E45. (Suppl),.
130. Cole S.W., Naliboff B.D., Kemeny M.E., et al. Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity. Proc. Natl. Acad. Sci. USA, 2001, 98:12695-12700.
131. Cole S.W., Jamieson B.D., Zack J.A. cAMP upregulates cell surface expression of lymphocyte CXCR4: implications for chemotaxis and HIV-1 infection. J. Immunol. 1999, 162:1392-1400.
132. Cole S.W., Korin Y.D., Fahey J.L., et al. Norepinephrine accelerates HIV replication via protein kinase Adependent effects on cytokine production. J. Immunol. 1998, 161:610-616.
133. Killebrew D., Shiramizu B. Pathogenesis of HIVassociated non-Hodgkin lymphoma. Curr. HIV Res. 2004, 2:215-221.
134. Clifford G.M., Polesel J., Rickenbach M., et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J. Natl. Cancer Inst. 2005, 97:425-432.
135. Chang M. Beta-adrenoreceptors reactivate KSHV lytic replication via PKA-dependent control of viral RTA. Journal of Virology 2005, In press,.
136. Turgeman H., Aboud M. Evidence that protein kinase A activity is required for the basal and tax-stimulated transcriptional activity of human T-cell leukemia virus type-I long termi. FEBS Lett. 1998, 428:183-187.
137. Bhopale G.M., Nanda R.K. Prospects for hepatitis C vaccine. Acta Virol. 2004, 48:215-221.
138. Harper D.M. Efficacy of a bivalent L1 virus-like PARTicle vaccine in prevention of infection with human papillomavirus types 16 and18 in young women: a randomized trial. Obstet. Gynecol. Surv. 2005, 60:171-173.
139. Marsland A.L., Cohen S., Rabin B.S., et al. Associations between stress, trait negative affect, acute immune reactivity, and antibody response to hepatitis B injection in healthy young adults. Health Psychol. 2001, 20:4-11.
140. Jabaaij L., van Hattum J., Vingerhoets J.J., et al. Modulation of immune response to rDNA hepatitis B vaccination by psychological stress. J. Psychosom. Res. 1996, 41:129-137.
141. Jabaaij L., Grosheide P.M., Heijtink R.A., et al. influence of perceived psychological stress and distress on antibody response to low dose rDNA hepatitis B vaccine. J. Psychosom. Res. 1993, 37:361-369.
142. Glaser R., Kiecolt-Glaser J.K., Bonneau R.H., et al. Stress-induced modulation of the immune response to recombinant hepatitis B vaccine. Psychosomatic Medicine 1992, 54:22-29.
143. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews. Cancer, 2003, 3:453-458.
144. Fidler I.J. Critical determinants of metastasis. Seminars in Cancer Biology 2002, 12:89-96.
145. Fidler I.J. Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Research 1990, 50:6130-6138.
146. Folkman J. Toward an understanding of angiogenesis: search and discovery. Perspectives in Biology & Medicine 1985, 29:10-36.
147. Auerbach W., Auerbach R. Angiogenesis inhibition: a review. Pharmacology & Therapeutics 1994, 63:265-311.
148. Fidler I.J. Critical factors in the biology of human cancer metastasis. Am. Surg. 1995, 61:1065-1066.
149. Fidler I.J. Modulation of the organ microenvironment for treatment of cancer metastasis. J. Natl. Cancer Inst. 1995, 87:1588-1592.
150. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1989, 8:98-101.
151. Mueller A.M., Fusenig N.E. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4:839-849.
152. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2:563-572.
153. Muller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
154. Liotta L.A. An attractive force in metastasis. Nature 2001, 410:24-25.
155. Sheridan J.F., Feng N.G., Bonneau R.H., et al. Restraint stress differentially affects anti-viral cellular and humoral immune responses in mice. J. Neuroimmunol. 1991, 31:245-255.
156. Padgett D.A., Marucha P.T., Sheridan J.F. Restraint stress slows cutaneous wound healing in mice. Brain Behav. Immun. 1998, 12:64-73.
157. Padgett D.A., Sheridan J.F., Dorne J., et al. Social stress and the reactivation of latent herpes simplex virus type 1. Proc. Natl. Acad. Sci. USA, 1998, 95:7231-7235.
158. Iwakabe K., Shimada M., Ohta A., et al. The restraint stress drives a shift in Th1/Th2 balance toward Th2-dominant immunity in mice. Immunology Letters 1998, 62:39-43.
159. Fiserova A., Starec M., Kuldova M., et al. Effects of D2-dopamine and alpha-adrenoceptor antagonists in stress induced changes on immune responsiveness of mice. Journal of Neuroimmunology 2002, 130:55-65.
160. Nukina H., Sudo N., Aiba Y., et al. Restraint stress elevates the plasma interleukin-6 levels in germ-free mice. J. Neuroimmunol. 2001, 115:46-52.
161. Zhou D., Kusnecov A.W., Shurin M.R., et al. Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamicpituitary-adrenal axis. Endocrinology 1993, 133:2523-2530.
162. Zorzet S., Perissin L., Rapozzi V., et al. Restraint stress reduces the antitumor efficacy of cyclophosphamide in tumorbearing mice. Brain Behav. Immun. 1998, 12:23-33.
163. Ghoshal K., Wang Y., Sheridan J.F., et al. Metallothionein induction in response to restraint stress. Transcriptional control, adaptation to stress, and role of glucocorticoid. Journal of Biological Chemistry 1998, 273:27904-27910.
164. Steplewski Z., Vogel W.H., Ehya H., et al. Effects of restraint stress on inoculated tumor growth and immune response in rats. Cancer Res. 1985, 45:5128-5133.
165. Cao L., Filipov N.M., Lawrence D.A. Sympathetic nervous system plays a major role in acute cold/restraint stress inhibition of host resistance to. Listeria monocytogenes. Journal of Neuroimmunology 2002, 125:94-102.
166. Steplewski Z., Goldman P.R., Vogel W.H. Effect of housing stress on the formation and development of tumors in rats. Cancer Lett. 1987, 34:257-261.
167. Tjurmina O.A., Armando I., Saavedra J.M., et al. Exaggerated adrenomedullary response to immobilization in mice with targeted disruption of the serotonin transporter gene. Endocrinology 2002, 143:4520-4526.
168. Kvetnansky R., Fukuhara K., Pacak K., et al. Endogenous glucocorticoids restrain catecholamine synthesis and release at rest and during immobilization stress in rats. Endocrinology 1993, 133:1411-1419.
169. Ben-Eliyahu S., Page G.G., Yirmiya R., et al. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. International Journal of Cancer 1999, 80:880-888.
170. Page G.G., Ben-Eliyahu S. A role for NK cells in greater susceptibility of young rats to metastatic formation. Developmental & Comparative Immunology 1999, 23:87-96.
171. Page G.G., Ben-Eliyahu S., Yirmiya R., et al. Morphine attenuates surgery-induced enhancement of metastatic colonization in rats. Pain 1993, 54:21-28.
172. Flaxman B.A., Harper R.A. In vitro analysis of the control of keratinocyte proliferation in human epidermis by physiologic and pharmacologic agents. J. Invest. Dermatol 1975, 65:52-59.
173. Vandewalle B., Revillion F., Lefebvre J. Functional beta-adrenergic receptors in breast cancer cells. J. Cancer Res. Clin. Oncol. 1990, 116:303-306.
174. Marchetti B., Spinola P.G., Pelletier G., et al. A potential role for catecholamines in the development and progression of carcinogen-induced mammary tumors: hormonal control of beta-adrenergic receptors and correlation with tumor growth. Journal of Steroid Biochemistry & Molecular Biology, 1991, 38:307-320.
175. Abramovitch R., Tavor E., Jacob-Hirsch J., et al. A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res. 2004, 64:1338-1346.
176. Lang K., Drell T., Lt.Lindecke A., et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int. J. Cancer. 2004, 112:231-238.
177. Jean D., Bar-Eli M. Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Mol. Cell. Biochem. 2000, 212:19-28.
178. Scarparo A.C., Sumida D.H., Patrao M.T., et al. Catecholamine effects on human melanoma cells evoked by alpha1-adrenoceptors. Arch. Dermatol. Res. 2004, 296:112-119.
179. PiflC., Zezula J., Spittler A., et al. Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter. FASEB J. 2001, 15:1607-1609.
180. Bijman J.T., Wagener D.J., Graafsma S.J., et al. Modulation of proliferation of a human head and neck squamous carcinoma cell line (HN-1) by catecholamines and histamine. Anticancer Res. 1987, 7:147-150.
181. Cox M.E., Deeble P.D., Lakhani S., et al. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res. 1999, 59:3821-3830.
182. Cohen R.J., Glezerson G., Haffejee Z. Neuroendocrine cells-a new prognostic parameter in prostate cancer. Br. J. Urol. 1991, 68:258-262.
183. Theodorescu D., Broder S.R., Boyd J.C., et al. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer, 1997, 80:2109-2119.
184. di Sant'Agnese P.A. Neuroendocrine differentiation in human prostatic carcinoma. Hum. Pathol. 1992, 23:287-296.
185. Zhao X.Y., Malloy P.J., Krishnan A.V., et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 2000, 6:703-706.
186. Simon W.E., Albrecht M., Trams G., et al. In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen, and prolactin. J. Natl. Cancer Inst. 1984, 73:313-321.
187. Boudreau N., Bissell M.J. Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr. Opin. Cell Biol. 1998, 10:640-646.
188. Hay E. Biology of the extracellular matrix 1991, Plenum Press, New York.
189. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992, 69:11-25.
190. Mercurio A.M., Rabinovitz I. Towards a mechanistic understanding of tumor invasion-lessons from the alpha6beta 4 integrin. Semin. Cancer Biol. 2001, 11:129-141.
191. Kawasaki H., Springett G.M., Mochizuki N., et al. A family of cAMP-binding proteins that directly activate Rap1. Science 1998, 282:2275-2279.
192. de Rooij J., Zwartkruis F.J., Verheijen M.H., et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998, 396:474-477.
193. Rangarajan S., Enserink J.M., Kuiperij H.B., et al. Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the beta 2-adrenergic receptor. J. Cell Biol. 2003, 160:487-493.
194. Enserink J.M., Price L.S., Methi T., et al. The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the alpha3beta1 integrin but not the alpha6beta4 integrin. J. Biol. Chem. 2004, 279:44889-44896.
195. Liotta L.A., Stetler-Stevenson W.G. Metalloproteinases and cancer invasion. Semin. Cancer Biol. 1990, 1:99-106.
196. Drell T.Lt., Joseph J., Lang K., et al. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDAMB-468 human breast carcinoma cells. Breast Cancer Res. Treat, 2003, 80:63-70.
197. Masur K., Niggemann B., Zanker K.S., et al. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res. 2001, 61:2866-2869.
198. Sood, A. K., Bhatty, R., Landen, C. N. Jr., et al. (In press). Stress hormone mediated invasion of ovarian cancer cells. Clinical Cancer Research.
199. Sood A.K., Lush R., Geisler J.P., et al. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clinical Cancer Research, 2004, 10:6080-6085.
200. Fredriksson J.M., Lindquist J.M., Bronnikov G.E., et al. Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta-adrenoreceptor/cAMP/protein kinase A pathway invo but independently of Erk1/2. Journal of Biological Chemistry 2000, 275:13802-13811.
201. Ferrara N. Vascular endothelial growth factor. European Journal of Cancer, 1996, 32A:2413-2422.
202. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Reviews, 1997, 18:4-25.
203. Thaker P.H., Lloyd M., Jennings N., et al. Chronic stress promotes angiogenesis in ovarian carcinoma. The 36thAnnual Meeting of the Society of Gynecologic Oncologists 2005.
204. Lutgendorf S.K., Johnsen E.L., Cooper B., et al. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer 2002, 95:808-815.
205. Costanzo E.S., Lutgendorf S.K., Sood A.K., et al. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer, 2005, 104:305-313.
206. Kaiserlian D., Savino W., Hassid J., et al. Studies of the thymus in mice bearing the Lewis lung carcinoma. III. Possible mechanisms of tumor-induced thymic atrophy. Clin. Immunol. Immunopathol. 1984, 32:316-325.
207. Gabrilovich D.I., Chen H.L., Girgis K.R., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996, 2:1096-1103.
208. Gabrilovich D., Ishida T., Oyama T., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages. Blood 1998, 92:4150-4166.
209. Ohm J.E., Gabrilovich D.I., Sempowski G.D., et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003, 101:4878-4886.
210. Frassanito M.A., Cusmai A., Iodice G., et al. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001, 97:483-489.
211. Machein M.R., Kullmer J., Ronicke V., et al. Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathology & Applied Neurobiology 1999, 25:104-112.
212. Distelhorst C.W. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ. 2002, 9:6-19.
213. Herr I., Ucur E., Herzer K., et al. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res. 2003, 63:3112-3120.
214. Wu W., Chaudhuri S., Brickley D.R., et al. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res. 2004, 64:1757-1764.
215. Dave J.R., Anderson S.M., Saviolakis G.A., et al. Chronic sustained stress increases levels of anterior pituitary prolactin mRNA. Pharmacol. Biochem. Behav. 2000, 67:423-431.
216. Almeida S.A., Petenusci S.O., Franci J.A., et al. Chronic immobilization-induced stress increases plasma testosterone and delays testicular maturation in pubertal rats. Andrologia. 2000, 32:7-11.
217. Young W.S., 3rd Lightman S.L. Chronic stress elevates enkephalin expression in the rat paraventricular and supraoptic nuclei. Mol. Brain Res. 1992, 13:111-117.
218. Clevenger C.V., Furth P.A., Hankinson S.E., et al. The role of prolactin in mammary carcinoma. Endocr. Rev. 2003, 24:1-27.
219. Ben-Jonathan N., Liby K., McFarland M., et al. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol. Metab. 2002, 13:245-250.
220. Vonderhaar B.K. Prolactin in human breast cancer development. Endocrine oncology 2000, 101-120. Humana Press, Totowa. S. P. Ethier (Ed.).
221. Chen W.Y., Ramamoorthy P., Chen N., et al. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin. Cancer Res. 1999, 5:3583-3593.
222. Richert M.M., Decker K., Anderson S.M. Mechanisms underlying constitutive activation of Akt in breast cancer cell lines. 83rd Annual Meeting of the Endocrine Society 2001, 551.
223. Pequeux C., Keegan B.P., Hagelstein M.T., et al. Oxytocin-and vasopressin-induced growth of human smallcell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr. Relat. Cancer 2004, 11:871-885.
224. Cassoni P., Marrocco T., Deaglio S., et al. Biological relevance of oxytocin and oxytocin receptors in cancer cells and primary tumors. Ann. Oncol. 2001, 12(Suppl 2):S37-S39.
225. Taylor A.H., Ang V.T., Jenkins J.S., et al. Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res. 1990, 50:7882-7886.
226. Bussolati G., Cassoni P. Editorial: the oxytocin/oxytocin receptor system-expect the unexpected. Endocrinology 2001, 142:1377-1379.
227. Glavin GB, Szabo S. Dopamine in gastrointestinal disease. Dig. Dis. Sci. 1990, 35:1153-1161.
228. Mezey E., Eisenhofer G., Hansson S., et al. Dopamine produced by the stomach may act as a paracrine/autocrine hormone in the rat. Neuroendocrinology 1998, 67:336-348.
229. Imperato A,.Angelucci L., Casolini P., et al. Repeated stressful experiences differently affect limbic dopamine release during and following stress. Brain Res. 1992, 577:194-199.
230. Isovich E., Mijnster M.J., Flugge G., et al. Chronic psychosocial stress reduces the density of dopamine transporters. Eur. J. Neurosci. 2000, 12:1071-1078.
231. Johnson D.E., Ochieng J., Evans S.L. The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells. Anticancer Drugs 1995, 6:471-474.
232. Lai C.T., Yu P.H. Dopamine-and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa) -induced cytotoxicity towards catecholaminergic neuroblastoma SHSY5Y cells. Effects of o stress and antioxidative factors. Biochem. Pharmacol. 1997, 53:363-372.
233. Wick M.M. Levodopa and dopamine analogs as DNA polymerase inhibitors and antitumor agents in human melanoma. Cancer Res. 1980, 40:1414-1418.
234. Wick M.M., Mui A. Synthesis and biologic evaluation of the dopamine analog N-acetyldopamine in experimental leukemia in mice. J. Natl. Cancer Inst. 1981, 66:351-354.
235. Fitzgerald G.B., Wick M.M. Comparison of the inhibitory effects of hydroxyurea, 5-fluorodeoxyuridine, 3,4-dihydroxybenzylamine, and methotrexate on human squamous cell carcinoma. J. Invest. Dermatol. 1987, 88:66-70.
236. Chakroborty D., Sarkar C., Mitra R.B., et al. Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin. Cancer Res. 2004, 10:4349-4356.
237. Teunis M.A., Kavelaars A., Voest E., et al. Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. FASEB J. 2002, 16:1465-1467.
238. Basu S., Nagy J.A., Pal S., et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nature Medicine 2001, 7:569-574.
239. Perron L., Bairati I., Harel F., et al. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control, 2004, 15:535-541.
240. Algazi M., Plu-Bureau G., Flahault A., et al. Could treatments with beta-blockers be associated with a reduction in cancer risk?. Rev. Epidemiol. Sante Publique, 2004, 52:53-65.
241. Li C.I., Malone K.E., Weiss N.S., et al. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 2003, 98:1504-1513.
242. Meier C.R., Derby L.E., Jick A.S., et al. Angiotensinconverting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch. Intern. Med. 2000, 160:349-353.
243. Rosenberg L., Rao R.S., Palmer J.R., et al. Calcium channel blockers and the risk of cancer. JAMA, 1998, 279:1000-1004.
244. Lieb J. Antidepressants, eicosanoids and the prevention and treatment of cancer. A review Prostaglandins Leukot. Essent. Fatty Acids 2001, 65:233-239.